SSX2 and pachyonychia congenita: While some CTAs are especially prevalent in advanced or metastatic disease [21] such as SSX2 [22], significant heterogeneity in the expression profile of CTAs has been observed between different cancers including PC, tumor loci within the same host, or even within the same lesion [23–25].